Epilepsy Drugs Market Size and Forecasts (2020 – 2030)

Epilepsy Drugs Market Size and Forecasts (2020 – 2030), Global and Regional Share, Trends, and Growth Opportunity Analysis By Treatment (First Generation Anti-Epileptics, Second Generation Anti-Epileptics,  and Third Generation Anti-Epileptics), Distribution Channel (Hospital Pharmacy, Retail Pharmacy Stores, and Others), and Geography (North America, Europe, Asia Pacific, Middle East & Africa, and South & Central America)

Send Enquiry
Item ID: TIPRE00024323 Category: Tags: , ,

$3,185$5,985

Description

The epilepsy drugs market size was valued at US$ 7.768 billion in 2022 and is projected to reach US$ 10.705 billion by 2030; it is estimated to register a CAGR of 4.1% from 2022 to 2030. The epilepsy drugs market growth is primarily driven by the increasing prevalence of epilepsy and an increasing number of elderly people.

Epilepsy is a neurological condition that can cause seizures and affects millions of people globally. Epilepsy drugs are also known as anti-epileptic drugs (AEDs), which are commonly used for the treatment of epilepsy as it helps in the better management of seizures among epilepsy patients. Some of the patients with drugs resistance epilepsy opt for other treatment methods such as surgery and devices that are implanted in the brain to helps in seizure management.

Several Epilepsy Drugs Nearing Patent Expiration Creating Opportunities for Epilepsy Drugs Market Growth

Many patents expiries are anticipated in the epilepsy drugs market in the upcoming years. It is likely to increase the penetration of generic products to cut down healthcare expenses. This will generate additional opportunities for other market players. Below mentioned are some drugs that are nearing patent expiration in the next couple of years.

Company Patent Patent Expiration Date Ingredient Treatment

Sumitomo Pharma Co US9206135 April 21, 2026 ESLICARBAZEPINE ACETATE Partial-onset Seizures Epilepsy

GlaxoSmithKline US7919115 January 4, 2029 LAMOTRIGINE Epilepsy

Ucb Inc USRE38551 March 17, 2022 Lacosamide Epilepsy and Partial-onset Seizures

SK Biopharmaceuticals US7598279 October 30, 2027 CENOBAMATE Partial Epilepsies

SUPERNUS PHARMS US8877248 November, 2027 Sustained-release formulations of Topiramate Epilepsy

SUPERNUS PHARMS US9555004 November, 2027 Sustained-release formulations of Topiramate Epilepsy

SUPERNUS PHARMS US10314790 November, 2027 Sustained-release formulations of Topiramate Epilepsy

SUPERNUS PHARMS US8663683 November, 2027 Sustained-release formulations of Topiramate Epilepsy

SUPERNUS PHARMS US9622983 November, 2027 Sustained-release formulations of Topiramate Epilepsy

SUPERNUS PHARMS US8298580 November, 2027 Sustained-release formulations of Topiramate Epilepsy

SUPERNUS PHARMS US8992989 November, 2027 Sustained-release formulations of Topiramate Epilepsy

SUPERNUS PHARMS US8889191 November, 2027 Sustained-release formulations of Topiramate Epilepsy

SUPERNUS PHARMS US9549940 November, 2027 Sustained-release formulations of Topiramate Epilepsy

SUPERNUS PHARMS US8298576 April, 2028 Sustained-release formulations of Topiramate Epilepsy

Treatment-Based Insights

The epilepsy drugs market, by treatment, is segmented into first generation anti-epileptics, second generation anti-epileptics, and third generation anti-epileptics. In 2022, the second generation anti-epileptics segment held the largest market share; the third generation anti-epileptics is estimated to register the fastest CAGR during 2022–2030. The second-generation AEDs include felbamate, gabapentin, lamotrigine, levetiracetam, oxcarbazepine, pregabalin, rufinamide, stiripentol, tiagabine, topirate, topiramate, vigabatrin, and zonisamide. In North America and Europe, ZNS is also considered a second-generation drug. The higher cost of second-generation AEDs compared with first-generation drugs is a significant factor limiting their mention in formularies. The second-generation AEDs have a more favorable side-effect profile and a lower risk of teratogenesis compared with first-generation drugs. Many first-generation and several second-generation (AEDs) share a common feature of enzyme induction that can increase the metabolism of different substrates targeted by the cytochrome p450 enzyme, along with a decrease in the action of the inducer.

Distribution Channel-Based Insights

The epilepsy drugs market, by distribution channel, is segmented into hospital pharmacy, retail pharmacy stores, and others. In 2022, the hospital pharmacies segment held the largest market share; the retail pharmacy segment is anticipated to register the fastest CAGR during 2022–2030. Hospital pharmacies purchase pharmaceuticals from different companies and supply them to hospitals for outpatient or inpatient treatments. Hospital pharmacies usually offer therapeutic and critical care drugs that have applications in cardiology, neurology, urology, pathology, hematology, and dermatology. Hospital pharmacies are among the essential parts of the healthcare system of any country. These pharmacies maintain stocks of epilepsy drugs to ensure their ready availability for patients. Thus, hospital pharmacies hold a considerable size of the epilepsy drug market.

A few of the major primary and secondary sources referred to while preparing the report on the epilepsy drugs market are the World Health Organization (WHO), Centers for Disease Control and Prevention (CDC), National Center for Biotechnology Information (NCBI), Investor presentations and Annual Reports of Market players.

Summary Info

Industry:

Number of pages:

Pricing options:

, ,

Publishing status:

Geographical coverage:

Year of Publication:

Second-Generation Anti-epileptics Segment Held Largest Share of Type Segment in Epilepsy Drugs Market

According to our latest study on ” Epilepsy Drugs Market Size and Forecasts (2020 – 2030), Global and Regional Share, Trends, and Growth Opportunity Analysis – by Treatment, Distribution Channel, and Geography,” the epilepsy drugs market size was valued at US$ 7.768 billion in 2022 and is projected to reach US$ 10.705 billion by 2030; it is estimated to register a CAGR of 4.1% from 2022 to 2030. The report highlights the key factors and trends impacting the epilepsy drugs market growth and focuses on prominent players and their strategies.

Based on treatment, the epilepsy drugs market is segmented into first generation anti-epileptics, second generation anti-epileptics, and third generation anti-epileptics. In 2022, the second generation anti-epileptics segment held the largest market share in epilepsy drugs market; the third generation anti-epileptics is estimated to register the fastest CAGR during 2022–2030. The second-generation AEDs include felbamate, gabapentin, lamotrigine, levetiracetam, oxcarbazepine, pregabalin, rufinamide, stiripentol, tiagabine, topirate, topiramate, vigabatrin, and zonisamide. In North America and Europe, ZNS is also considered a second-generation drug. The higher cost of second-generation AEDs compared with first-generation drugs is a significant factor limiting their mention in formularies. The second-generation AEDs have a more favorable side-effect profile and a lower risk of teratogenesis compared with first-generation drugs. Many first-generation and several second-generation (AEDs) share a common feature of enzyme induction that can increase the metabolism of different substrates targeted by the cytochrome p450 enzyme, along with a decrease in the action of the inducer.

The third-generation AEDs mainly include eslicarbazepine acetate, lacosamide, and Cannabidiol. The drugs are claimed to be superior to previously known first- and second-generation AEDs in terms of safety and efficacy. The majority of new AEDs are used to control focal seizures, as well as in specific epileptic syndromes (Lennox–Gastaut syndrome and Dravet syndrome) and tuberous sclerosis. Third-generation AEDs have fewer adverse side effects, resulting in increased patient treatment adherence. The majority of new AEDs are used to control focal seizures, as well as in specific epileptic syndromes. Most of these third-generation drugs are effective, safe, and generally well-tolerated in children. Third-generation drugs are gaining importance but are not prescribed as frequently as second-generation antiepileptic drugs.

Based on distribution channel, the epilepsy drugs market is segmented into hospital pharmacy, retail pharmacy stores, and others. In 2022, the hospital pharmacies segment held the largest market share in epilepsy drugs market; the retail pharmacy segment is anticipated to register the fastest CAGR during 2022–2030. Hospital pharmacies purchase pharmaceuticals from different companies and supply them to hospitals for outpatient or inpatient treatments. Hospital pharmacies usually offer therapeutic and critical care drugs that have applications in cardiology, neurology, urology, pathology, hematology, and dermatology. Hospital pharmacies are among the essential parts of the healthcare system of any country. These pharmacies maintain stocks of epilepsy drugs to ensure their ready availability for patients. Thus, hospital pharmacies hold a considerable size of the epilepsy drugs market.

Retail pharmacy stores sell prescription drugs, over-the-counter (OTC) drugs, and some fast-moving consumer goods, along with providing related services. The epilepsy need medication on an ongoing basis, making prescription-based medicines mandatory, which help in the expansion of retail pharmacies. Modern retail pharmacy chains are digitized, organized, and tech-enabled, which allows them to track medication inventories and sell 100% reliable goods. In addition, retail pharmacy chains provide value-added services for consumers having medical claims or insurance filing to be done. They can also be requested to refurbish previous bills or memos.

UCB SA, Novartis AG, Pfizer Inc, GSK Plc, Abbott Laboratories, Sanofi SA, Sumitomo Pharma company, Teva Pharmaceutical Industries Ltd, Catalyst Pharmaceuticals Inc, and Alkem Laboratories Ltd are among the key players operating in the global epilepsy drugs market.

Epilepsy Drugs Market, by Distribution Channel, 2022 and 2030 (%)

Source:the research team Analysis

The report segments the global epilepsy drugs market as follows:

The epilepsy drugs market is segmented based on treatment, distribution channel, and geography. Based on treatment, the market is classified into first generation anti-epileptics, second generation anti-epileptics, and third generation anti-epileptics. Based on distribution channel, the market is classified into hospital pharmacy, retail pharmacy stores, and others. Based on geography, the market is divided into North America (the US, Canada, and Mexico), Europe (the UK, Germany, France, Italy, Spain, and the Rest of Europe), Asia Pacific (China, Japan, India, South Korea, Australia, and the Rest of Asia Pacific), Middle East & Africa (the UAE, Saudi Arabia, South Africa, and the Rest of Middle East & Africa), and South & Central America (Brazil, Argentina, and the Rest of South & Central America).

– Save and reduce time carrying out entry-level research by identifying the growth, size, leading players, and segments in the Asia Pacific frozen waffles market.
– Highlights key business priorities in order to assist companies to realign their business strategies.
– the key findings and recommendations highlight crucial progressive industry trends in Asia Pacific frozen waffles market, thereby allowing players across the value chain to develop effective long-term strategies.
– develop/modify business expansion plans by using substantial growth offering developed and emerging markets.
– Scrutinize in-depth Asia Pacific market trends and outlook coupled with the factors driving the market, as well as those hindering it.
– Enhance the decision-making process by understanding the strategies that underpin security interest with respect to client products, segmentation, pricing and distribution.

TABLE OF CONTENTS

1. Introduction
1.1 Research Report Guidance
1.2 Market Segmentation
2. Executive Summary
2.1 Key Insights
2.2 Market Attractiveness
3. Research Methodology
3.1 Coverage
3.2 Secondary Research
3.3 Primary Research
4. Asia Pacific Chlorine Market Landscape
4.1 Overview
4.2 Porter’s Five Forces Analysis
4.2.1 Bargaining Power of Suppliers
4.2.2 Bargaining Power of Buyers
4.2.3 Threat of New Entrants
4.2.4 Competitive Rivalry
4.2.5 Threat of Substitutes
4.3 Ecosystem Analysis
4.3.1 Raw Material Suppliers
4.3.1.1 List of Vendors in the Value Chain
4.3.2 Manufacturers
4.3.3 Distributors/Suppliers
4.3.4 End-Use Industry
5. Asia Pacific Chlorine Market – Key Market Dynamics
5.1 Market Drivers
5.1.1 Growing Demand from Water and Wastewater Treatment Industry
5.1.2 Flourishment of PVC Manufacturing Industry
5.2 Market Restraints
5.2.1 Stringent Government Regulations for Environment Protection
5.3 Market Opportunity
5.3.1 Growing Adoption from End-Use Industries
5.4 Future Trends
5.4.1 Development of Greener Chlorine
5.5 Impact Analysis
6. Chlorine Market – Asia Pacific Market Analysis
6.1 Asia Pacific Chlorine Market Revenue (US$ Million)
6.2 Asia Pacific Chlorine Market Forecast and Analysis
7. Asia Pacific Chlorine Market Analysis – Application
7.1 Ethylene Dichloride/Polyvinylchloride Production
7.1.1 Overview
7.1.2 Ethylene Dichloride/Polyvinylchloride Production Market Revenue and Forecast to 2030 (US$ Million)
7.2 Chloromethanes
7.2.1 Overview
7.2.2 Chloromethanes Market Revenue and Forecast to 2030 (US$ Million)
7.3 Isocyanates and Oxygenates
7.3.1 Overview
7.3.2 Isocyanates and Oxygenates Market Revenue and Forecast to 2030 (US$ Million)
7.4 Solvents
7.4.1 Overview
7.4.2 Solvents Market Revenue and Forecast to 2030 (US$ Million)
7.5 Others
7.5.1 Overview
7.5.2 Others Market Revenue and Forecast to 2030 (US$ Million)
8. Asia Pacific Chlorine Market Analysis – End-Use Industry
8.1 Water Treatment
8.1.1 Overview
8.1.2 Water Treatment Market Revenue, and Forecast to 2030 (US$ Million)
8.2 Chemicals
8.2.1 Overview
8.2.2 Chemicals Market Revenue, and Forecast to 2030 (US$ Million)
8.3 Pulp and Paper
8.3.1 Overview
8.3.2 Pulp and Paper Market Revenue and Forecast to 2030 (US$ Million)
8.4 Plastics
8.4.1 Overview
8.4.2 Plastics Market Revenue and Forecast to 2030 (US$ Million)
8.5 Pharmaceuticals
8.5.1 Overview
8.5.2 Pharmaceuticals Market Revenue and Forecast to 2030 (US$ Million)
8.6 Others
8.6.1 Overview
8.6.2 Others Market Revenue and Forecast to 2030 (US$ Million)
9. Asia Pacific Chlorine Market – Country Analysis
9.1 Asia Pacific Chlorine Market
9.1.1 Overview
9.1.2 Asia Pacific Chlorine Market, By Key Country- Revenue 2022 (US$ Million)
9.1.3 Asia Pacific Chlorine Market Breakdown by Country
9.1.3.1 Asia Pacific Chlorine Market Breakdown by Country
9.1.3.2 Australia Chlorine Market Revenue and Forecasts To 2030 (US$ Million)
9.1.3.2.1 Australia Chlorine Market Breakdown by Application
9.1.3.2.2 Australia Chlorine Market Breakdown by End-Use Industry
9.1.3.3 China Chlorine Market Revenue and Forecasts To 2030 (US$ Million)
9.1.3.3.1 China Chlorine Market Breakdown by Application
9.1.3.3.2 China Chlorine Market Breakdown by End-Use Industry
9.1.3.4 India Chlorine Market Revenue and Forecasts To 2030 (US$ Million)
9.1.3.4.1 India Chlorine Market Breakdown by Application
9.1.3.4.2 India Chlorine Market Breakdown by End-Use Industry
9.1.3.5 Japan Chlorine Market Revenue and Forecasts To 2030 (US$ Million)
9.1.3.5.1 Japan Chlorine Market Breakdown by Application
9.1.3.5.2 Japan Chlorine Market Breakdown by End-Use Industry
9.1.3.6 South Korea Chlorine Market Revenue and Forecasts To 2030 (US$ Million)
9.1.3.6.1 South Korea Chlorine Market Breakdown by Application
9.1.3.6.2 South Korea Chlorine Market Breakdown by End-Use Industry
9.1.3.7 Rest of Asia Pacific Chlorine Market Revenue and Forecasts To 2030 (US$ Million)
9.1.3.7.1 Rest of Asia Pacific Chlorine Market Breakdown by Application
9.1.3.7.2 Rest of Asia Pacific Chlorine Market Breakdown by End-Use Industry
10. Competitive Landscape
10.1 Heat Map Analysis by Key Players
10.2 Company Positioning & Concentration
11. Industry Landscape
11.1 Overview
11.2 Market Initiative
11.3 New Product Development
11.4 Merger and Acquisition
12. Company Profiles
12.1 Aditya Birla Chemicals India Ltd
12.1.1 Key Facts
12.1.2 Business Description
12.1.3 Products and Services
12.1.4 Financial Overview
12.1.5 SWOT Analysis
12.1.6 Key Developments
12.2 BASF SE
12.2.1 Key Facts
12.2.2 Business Description
12.2.3 Products and Services
12.2.4 Financial Overview
12.2.5 SWOT Analysis
12.2.6 Key Developments
12.3 Ercros SA
12.3.1 Key Facts
12.3.2 Business Description
12.3.3 Products and Services
12.3.4 Financial Overview
12.3.5 SWOT Analysis
12.3.6 Key Developments
12.4 Hanwha Solutions Corp
12.4.1 Key Facts
12.4.2 Business Description
12.4.3 Products and Services
12.4.4 Financial Overview
12.4.5 SWOT Analysis
12.4.6 Key Developments
12.5 INEOS Group Holdings SA
12.5.1 Key Facts
12.5.2 Business Description
12.5.3 Products and Services
12.5.4 Financial Overview
12.5.5 SWOT Analysis
12.5.6 Key Developments
12.6 Occidental Petroleum Corp
12.6.1 Key Facts
12.6.2 Business Description
12.6.3 Products and Services
12.6.4 Financial Overview
12.6.5 SWOT Analysis
12.6.6 Key Developments
12.7 Olin Corp
12.7.1 Key Facts
12.7.2 Business Description
12.7.3 Products and Services
12.7.4 Financial Overview
12.7.5 SWOT Analysis
12.7.6 Key Developments
12.8 Tata Chemicals Ltd
12.8.1 Key Facts
12.8.2 Business Description
12.8.3 Products and Services
12.8.4 Financial Overview
12.8.5 SWOT Analysis
12.8.6 Key Developments
12.9 Sumitomo Chemical Co Ltd
12.9.1 Key Facts
12.9.2 Business Description
12.9.3 Products and Services
12.9.4 Financial Overview
12.9.5 SWOT Analysis
12.9.6 Key Developments
13. Appendix

LIST OF TABLES

Table 1. Epilepsy Drugs Segmentation
Table 2. North America Epilepsy Drugs Market, by Treatment – Revenue and Forecast to 2030 (US$ Million)
Table 3. North America Epilepsy Drugs Market, by Distribution Channel – Revenue and Forecast to 2030 (US$ Million)
Table 4. US Epilepsy Drugs Market, by Treatment – Revenue and Forecast to 2030 (US$ Million)
Table 5. US Epilepsy Drugs Market, by Distribution Channel – Revenue and Forecast to 2030 (US$ Million)
Table 6. Canada Epilepsy Drugs Market, by Treatment – Revenue and Forecast to 2030 (US$ Million)
Table 7. Canada Epilepsy Drugs Market, by Distribution Channel – Revenue and Forecast to 2030 (US$ Million)
Table 8. Mexico Epilepsy Drugs Market, by Treatment – Revenue and Forecast to 2030 (US$ Million)
Table 9. Mexico Epilepsy Drugs Market, by Distribution Channel – Revenue and Forecast to 2030 (US$ Million)
Table 10. Europe Epilepsy Drugs Market, by Treatment – Revenue and Forecast to 2030 (US$ Million)
Table 11. Europe Epilepsy Drugs Market, by Distribution Channel – Revenue and Forecast to 2030 (US$ Million)
Table 12. Germany Epilepsy Drugs Market, by Treatment – Revenue and Forecast to 2030 (US$ Million)
Table 13. Germany Epilepsy Drugs Market, by Distribution Channel – Revenue and Forecast to 2030 (US$ Million)
Table 14. France Epilepsy Drugs Market, by Treatment – Revenue and Forecast to 2030 (US$ Million)
Table 15. France Epilepsy Drugs Market, by Distribution Channel – Revenue and Forecast to 2030 (US$ Million)
Table 16. UK Epilepsy Drugs Market, by Treatment – Revenue and Forecast to 2030 (US$ Million)
Table 17. UK Epilepsy Drugs Market, by Distribution Channel – Revenue and Forecast to 2030 (US$ Million)
Table 18. Italy Epilepsy Drugs Market, by Treatment – Revenue and Forecast to 2030 (US$ Million)
Table 19. Italy Epilepsy Drugs Market, by Distribution Channel – Revenue and Forecast to 2030 (US$ Million)
Table 20. Spain Epilepsy Drugs Market, by Treatment – Revenue and Forecast to 2030 (US$ Million)
Table 21. Spain Epilepsy Drugs Market, by Distribution Channel – Revenue and Forecast to 2030 (US$ Million)
Table 22. Rest of Europe Epilepsy Drugs Market, by Treatment – Revenue and Forecast to 2030 (US$ Million)
Table 23. Rest of Europe Epilepsy Drugs Market, by Distribution Channel – Revenue and Forecast to 2030 (US$ Million)
Table 24. Asia Pacific Epilepsy Drugs Market, by Treatment – Revenue and Forecast to 2030 (US$ Million)
Table 25. Asia Pacific Epilepsy Drugs Market, by Distribution Channel – Revenue and Forecast to 2030 (US$ Million)
Table 26. China Epilepsy Drugs Market, by Treatment – Revenue and Forecast to 2030 (US$ Million)
Table 27. China Epilepsy Drugs Market, by Distribution Channel – Revenue and Forecast to 2030 (US$ Million)
Table 28. Japan Epilepsy Drugs Market, by Treatment – Revenue and Forecast to 2030 (US$ Million)
Table 29. Japan Epilepsy Drugs Market, by Distribution Channel – Revenue and Forecast to 2030 (US$ Million)
Table 30. India Epilepsy Drugs Market, by Treatment – Revenue and Forecast to 2030 (US$ Million)
Table 31. India Epilepsy Drugs Market, by Distribution Channel – Revenue and Forecast to 2030 (US$ Million)
Table 32. Australia Epilepsy Drugs Market, by Treatment – Revenue and Forecast to 2030 (US$ Million)
Table 33. Australia Epilepsy Drugs Market, by Distribution Channel – Revenue and Forecast to 2030 (US$ Million)
Table 34. South Korea Epilepsy Drugs Market, by Treatment – Revenue and Forecast to 2030 (US$ Million)
Table 35. South Korea Epilepsy Drugs Market, by Distribution Channel – Revenue and Forecast to 2030 (US$ Million)
Table 36. Rest of Asia Pacific Epilepsy Drugs Market, by Treatment – Revenue and Forecast to 2030 (US$ Million)
Table 37. Rest of Asia Pacific Epilepsy Drugs Market, by Distribution Channel – Revenue and Forecast to 2030 (US$ Million)
Table 38. Middle East & Africa Epilepsy Drugs Market, by Treatment – Revenue and Forecast to 2030 (US$ Million)
Table 39. Middle East & Africa Epilepsy Drugs Market, by Distribution Channel – Revenue and Forecast to 2030 (US$ Million)
Table 40. South Africa Epilepsy Drugs Market, by Treatment – Revenue and Forecast to 2030 (US$ Million)
Table 41. South Africa Epilepsy Drugs Market, by Distribution Channel – Revenue and Forecast to 2030 (US$ Million)
Table 42. Saudi Arabia Epilepsy Drugs Market, by Treatment – Revenue and Forecast to 2030 (US$ Million)
Table 43. Saudi Arabia Epilepsy Drugs Market, by Distribution Channel – Revenue and Forecast to 2030 (US$ Million)
Table 44. UAE Epilepsy Drugs Market, by Treatment – Revenue and Forecast to 2030 (US$ Million)
Table 45. UAE Epilepsy Drugs Market, by Distribution Channel – Revenue and Forecast to 2030 (US$ Million)
Table 46. Rest of Middle East & Africa Epilepsy Drugs Market, by Treatment – Revenue and Forecast to 2030 (US$ Million)
Table 47. Rest of Middle East & Africa Epilepsy Drugs Market, by Distribution Channel – Revenue and Forecast to 2030 (US$ Million)
Table 48. South & Central America: Epilepsy Drugs Market, by Treatment – Revenue and Forecast to 2030 (US$ Million)
Table 49. South & Central America: Epilepsy Drugs Market, by Distribution Channel – Revenue and Forecast to 2030 (US$ Million)
Table 50. Brazil: Epilepsy Drugs Market, by Treatment – Revenue and Forecast to 2030 (US$ Million)
Table 51. Brazil: Epilepsy Drugs Market, by Distribution Channel – Revenue and Forecast to 2030 (US$ Million)
Table 52. Argentina: Epilepsy Drugs Market, by Treatment – Revenue and Forecast to 2030 (US$ Million)
Table 53. Argentina: Epilepsy Drugs Market, by Distribution Channel – Revenue and Forecast to 2030 (US$ Million)
Table 54. Rest of South & Central America: Epilepsy Drugs Market, by Treatment – Revenue and Forecast to 2030 (US$ Million)
Table 55. Rest of South & Central America: Epilepsy Drugs Market, by Distribution Channel – Revenue and Forecast to 2030 (US$ Million)
Table 56. Recent Inorganic Growth Strategies in the Epilepsy Drugs Market
Table 57. Recent Organic Growth Strategies in the Epilepsy Drugs Market
Table 58. Glossary of Terms, Epilepsy Drugs Market

LIST OF FIGURES

Figure 1. Epilepsy Drugs Segmentation, By Geography
Figure 2. Global – PEST Analysis
Figure 3. Epilepsy Drugs Market: Key Industry Dynamics
Figure 4. Epilepsy Drugs Market: Impact Analysis of Drivers and Restraints
Figure 5. Epilepsy Drugs Revenue (US$ Mn), 2022 – 2030
Figure 6. Epilepsy Drugs Market Revenue Share, by Treatment 2022 & 2030 (%)
Figure 7. First Generation Anti-epileptics: Epilepsy Drugs Market – Revenue and Forecast to 2030 (US$ Million)
Figure 8. Second Generation Anti-epileptics: Epilepsy Drugs Market – Revenue and Forecast to 2030 (US$ Million)
Figure 9. Third Generation Anti-epileptics: Epilepsy Drugs Market – Revenue and Forecast to 2030 (US$ Million)
Figure 10. Epilepsy Drugs Market Revenue Share, by Distribution Channel 2022 & 2030 (%)
Figure 11. Hospital Pharmacy: Epilepsy Drugs Market – Revenue and Forecast to 2030 (US$ Million)
Figure 12. Retail Pharmacy Stores: Epilepsy Drugs Market – Revenue and Forecast to 2030 (US$ Million)
Figure 13. Others: Epilepsy Drugs Market – Revenue and Forecast to 2030 (US$ Million)
Figure 14. North America: Epilepsy Drugs Market, by Key Country – Revenue (2022) (US$ Million)
Figure 15. North America Epilepsy Drugs Market – Revenue and Forecast to 2030 (US$ Million)
Figure 16. North America: Epilepsy Drugs Market, by Country, 2022 & 2030 (%)
Figure 17. US: Epilepsy Drugs Market – Revenue and Forecast to 2030 (US$ Million)
Figure 18. Canada: Epilepsy Drugs Market – Revenue and Forecast to 2030 (US$ Million)
Figure 19. Mexico: Epilepsy Drugs Market – Revenue and Forecast to 2030 (US$ Million)
Figure 20. Europe: Epilepsy Drugs Market, by Key Country – Revenue (2022) (US$ Million)
Figure 21. Europe Epilepsy Drugs Market – Revenue and Forecast to 2030 (US$ Million)
Figure 22. Europe: Epilepsy Drugs Market, by Country, 2022 & 2030 (%)
Figure 23. Germany: Epilepsy Drugs Market – Revenue and Forecast to 2030 (US$ Million)
Figure 24. France: Epilepsy Drugs Market – Revenue and Forecast to 2030 (US$ Million)
Figure 25. UK: Epilepsy Drugs Market – Revenue and Forecast to 2030 (US$ Million)
Figure 26. Italy: Epilepsy Drugs Market – Revenue and Forecast to 2030 (US$ Million)
Figure 27. Spain: Epilepsy Drugs Market – Revenue and Forecast to 2030 (US$ Million)
Figure 28. Rest of Europe: Epilepsy Drugs Market – Revenue and Forecast to 2030 (US$ Million)
Figure 29. Asia Pacific: Epilepsy Drugs Market, by Key Country – Revenue (2022) (US$ Million)
Figure 30. Asia Pacific Epilepsy Drugs Market Revenue and Forecast to 2030 (US$ Million)
Figure 31. Asia Pacific: Epilepsy Drugs Market, by Country, 2022 & 2030 (%)
Figure 32. China: Epilepsy Drugs Market – Revenue and Forecast to 2030 (US$ Million)
Figure 33. Japan: Epilepsy Drugs Market – Revenue and Forecast to 2030 (US$ Million)
Figure 34. India: Epilepsy Drugs Market – Revenue and Forecast to 2030 (US$ Million)
Figure 35. Australia: Epilepsy Drugs Market – Revenue and Forecast to 2030 (US$ Million)
Figure 36. South Korea: Epilepsy Drugs Market – Revenue and Forecast to 2030 (US$ Million)
Figure 37. Rest of Asia Pacific: Epilepsy Drugs Market – Revenue and Forecast to 2030 (US$ Million)
Figure 38. Middle East & Africa: Epilepsy Drugs Market, by Key Country – Revenue (2022) (US$ Million)
Figure 39. Middle East & Africa Epilepsy Drugs Market – Revenue and Forecast to 2030 (US$ Million)
Figure 40. Middle East & Africa: Epilepsy Drugs Market, by Country, 2022 & 2030 (%)
Figure 41. South Africa: Epilepsy Drugs Market – Revenue and Forecast to 2030 (US$ Million)
Figure 42. Saudi Arabia: Epilepsy Drugs Market – Revenue and Forecast to 2030 (US$ Million)
Figure 43. UAE: Epilepsy Drugs Market – Revenue and Forecast to 2030 (US$ Million)
Figure 44. Rest of Middle East & Africa: Epilepsy Drugs Market – Revenue and Forecast to 2030 (US$ Million)
Figure 45. South & Central America: Epilepsy Drugs Market, By Key Country – Revenue (2022) (US$ Million)
Figure 46. South & Central America: Epilepsy Drugs Market- Revenue and Forecasts to 2030 (US$ Million)
Figure 47. South & Central America: Epilepsy Drugs Market Share by Country – 2022 & 2030, (%)
Figure 48. Brazil: Epilepsy Drugs Market- Revenue and Forecasts to 2030 (US$ Million)
Figure 49. Argentina: Epilepsy Drugs Market- Revenue and Forecasts to 2030 (US$ Million)
Figure 50. Rest of South & Central America: Epilepsy Drugs Market – Revenue and Forecast to 2030 (US$ Million)
Figure 51. Growth Strategies in the Epilepsy Drugs Market

The List of Companies – Epilepsy Drugs Market 
– UCB SA
– Novartis AG
– Pfizer Inc
– GSK Plc
– Abbott Laboratories
– Sanofi SA
– Sumitomo Pharma company
– Teva Pharmaceutical Industries Ltd
– Catalyst Pharmaceuticals Inc
– Alkem Laboratories Ltd
–  

Reviews

There are no reviews yet.

Be the first to review “Epilepsy Drugs Market Size and Forecasts (2020 – 2030)”